RPEP-09228 · 2024In 205 analyzed patients, erenumab and galcanezumab showed statistically significant improvements in MIDAS, HIT-6, monthly migraine days, and acute medication days. 17.5% reported adverse events (injection site pain, nausea, constipation, fatigue). Only 2.4% discontinued due to AEs, 7.3% for lack of efficacy.
Schweiger, Vittorio; Bellamoli, Paola; Taus, Francesco; Gottin, Leonardo; Martini, Alvise; Nizzero, Marta; Bonora, Eleonora; Del Balzo, Giovanna; Donadello, Katia; Secchettin, Erica; Finco, Gabriele; Santis, Daniele De; Polati, Enrico · Cohort
RPEP-09230 · 2024Semaglutide 2.4 mg vs placebo reduced all-cause death (HR 0.81, CI 0.71-0.93), non-CV death (HR 0.77, CI 0.62-0.95), and infectious death (HR 0.71, CI 0.51-0.98). Among COVID-19 patients, semaglutide reduced COVID deaths (HR 0.66, CI 0.44-0.96) and serious COVID events (232 vs 277, p=0.04). CV death trended lower (HR 0.85, CI 0.71-1.01).
Scirica, Benjamin M; Lincoff, A Michael; Lingvay, Ildiko; Bogdanski, Pawel; Buscemi, Silvio; Colhoun, Helen; Craciun, Anca-Elena; Ezhov, Marat; Hardt-Lindberg, Søren; Kleist Jeppesen, Ole; Matos, Ana Laura S A; Node, Koichi; Schiele, Francois; Toplak, Hermann; van Beek, André; Weeke, Peter E; Wiviott, Stephen D; Deanfield, John; Ryan, Donna · RCT
RPEP-09231 · 2024Pericardial effusion prevalence: 14.1-55.9% on echocardiography. LV systolic impairment: 0-4.25%. Myocardial inflammation: 0.6-21.8% on PET-CT. Only 1 study assessed cardiac biomarkers (BNP, troponin, CK-MB). Elevated troponin found in 246/800 patients. No CTCA studies identified.
Scopazzini, Marcello S; Hill, Katherine J; Majonga, Edith D; Zenner, Dominik; Ayles, Helen; Shah, Anoop S V · Meta Analysis
RPEP-09232 · 2024Weight loss interventions significantly improved HOMA-IR (-0.45, CI -0.75 to -0.15), free androgen index (-2.03, CI -3.0 to -1.07), and menstrual frequency (+2.64, CI 0.65-4.63). Nine trials used GLP-1 agonists. No significant effect on hirsutism or quality of life. Published in Annals of Internal Medicine.
Scragg, Jadine; Hobson, Alice; Willis, Lia; Taylor, Kathryn S; Dixon, Sharon; Jebb, Susan A · Meta Analysis
RPEP-09233 · 2024Severe hypoglycemia rates: glargine 0.8%, glimepiride 1.3%, liraglutide 0.5%, sitagliptin 0.3% (p<0.05). Hypoglycemic symptoms: glargine 54.2%, glimepiride 68.3%, liraglutide 32.4%, sitagliptin 29.1% (p<0.001). Liraglutide and sitagliptin had significantly less hypoglycemia than glimepiride and glargine.
Seaquist, Elizabeth R; Phillips, Lawrence S; Ghosh, Alokananda; Baker, Chelsea; Bergenstal, Richard M; Crandall, Jill P; Goland, Robin S; Gramzinski, Michaela R; Hox, Sophia H; Hsia, Daniel S; Johnson, Mary L; Lachin, John M; Raskin, Philip; Valencia, Willy M; Waltje, Andrea H; Younes, Naji · RCT
RPEP-09235 · 2024Cotadutide dose-dependently reduced UACR at week 14: 300 μg (-43.9%, CI -54.7 to -30.6) and 600 μg (-49.9%, CI -59.3 to -38.4) vs placebo. Effects sustained at 26 weeks. Safety of cotadutide 600 μg comparable to semaglutide. Serious AEs balanced across arms. 46.8% on concomitant SGLT2i.
Selvarajah, Viknesh; Robertson, Darren; Hansen, Lars; Jermutus, Lutz; Smith, Kirsten; Coggi, Angela; Sánchez, José; Chang, Yi-Ting; Yu, Hongtao; Parkinson, Joanna; Khan, Anis; Chung, H Sophia; Hess, Sonja; Dumas, Richard; Duck, Tabbatha; Jolly, Simran; Elliott, Tom G; Baker, John; Lecube, Albert; Derwahl, Karl-Michael; Scott, Russell; Morales, Cristobal; Peters, Carl; Goldenberg, Ronald; Parker, Victoria E R; Heerspink, Hiddo J L · RCT
RPEP-09236 · 2024500 patients surveyed (250 EM, 250 CM, 90% female). Mean 4.1 healthcare providers seen before diagnosis. 71% suspected migraine before diagnosis. 31% reluctant to seek care. 20% initially misdiagnosed. Prior preventives included anticonvulsants (61%), antidepressants (44%), blood pressure meds (43%), botulinum toxin (17%). Most discontinuations due to lack of efficacy or side effects.
Seng, Elizabeth; Lampl, Christian; Viktrup, Lars; Lenderking, William R; Karn, Hayley; Hoyt, Margaret; Kim, Gilwan; Ruff, Dustin; Ossipov, Michael H; Vincent, Maurice · Cohort
RPEP-09237 · 2024Collagen peptides significantly improved skin roughness, wrinkle peak-to-valley values, maximum peak height, and average maximum wrinkle height vs placebo. Overall, net, and biological elasticity significantly improved at week 12. Skin hydration and whitening (melanin, erythema) also significantly improved. Zero adverse events reported.
Seong, Seol Hwa; Lee, Young In; Lee, Joohee; Choi, Sooyeon; Kim, In Ah; Suk, Jangmi; Jung, Inhee; Baeg, Chaemin; Kim, Jinhak; Oh, Dongchan; Lee, Ju Hee · RCT
RPEP-09239 · 202442 patients treated with PRRT (5 with 90Y-DOTATOC, 37 with 177Lu-DOTATATE). Disease control rate: 57%. Median PFS: 16 months. Median OS: 36 months (63-month follow-up). 6 patients retreated with 177Lu-PRRT (retreatment PFS: 6.5 months, OS: 17 months). Only 1 treatment discontinuation for grade 3 platelet toxicity.
Severi, Stefano; Grassi, Ilaria; Bongiovanni, Alberto; Nicolini, Silvia; Marini, Irene; Arpa, Donatella; Ranallo, Nicoletta; Azzali, Irene; Di Iorio, Valentina; Sarnelli, Anna; Manuela, Monti; Amadori, Elena; Fabbri, Lucia; Bartolini, Daniela; Tosatto, Luigino; Di Meco, Francesco; Gurrieri, Lorena; Riva, Nada; Calabro, Luana; Matteucci, Federica; Paganelli, Giovanni; Sansovini, Maddalena · Cohort
RPEP-09240 · 2024GLP-1RAs vs insulin/no GLP-1RA: pooled HR 0.41 (CI 0.28-0.55), with considerable heterogeneity (I²=74%). GLP-1RAs vs metformin: HR 0.99 (not significant). GLP-1RAs vs DPP-4 inhibitors: HR 1.05 (not significant). GLP-1RAs vs sulfonylureas: HR 0.78 (CI 0.65-0.93).
Shabil, Muhammed; Khatib, Mahalaqua Nazli; Ballal, Suhas; Bansal, Pooja; Tomar, Balvir S; Ashraf, Ayash; Kumar, M Ravi; Sinha, Aashna; Rawat, Pramod; Gaidhane, Abhay M; Sah, Sanjit; Daniel, Afukonyo Shidoiku; Yappalparvi, Ambanna; Bushi, Ganesh · Meta Analysis
RPEP-09241 · 2024Weight loss consistent across diuretic groups (-6.9% to -8.8%, interaction P=0.39). KCCQ improvement greater in loop diuretic users (+9.3 vs +4.7 points, P=0.042). Loop diuretic dose decreased 17% with semaglutide vs +2.4% with placebo (P<0.0001). Semaglutide: OR 2.67 for dose reduction, OR 0.35 for dose increase. All secondary endpoints consistent across diuretic subgroups.
Shah, Sanjiv J; Sharma, Kavita; Borlaug, Barry A; Butler, Javed; Davies, Melanie; Kitzman, Dalane W; Petrie, Mark C; Verma, Subodh; Patel, Shachi; Chinnakondepalli, Khaja M; Einfeldt, Mette N; Jensen, Thomas J; Rasmussen, Søren; Asleh, Rabea; Ben-Gal, Tuvia; Kosiborod, Mikhail N · RCT
RPEP-09242 · 2024Single oral GENE/PTCA dose induced endogenous GLP-1 and insulin production in mice. Maintained normoglycemia for a prolonged period. Higher therapeutic efficacy than FDA-approved injectable semaglutide and liraglutide in preclinical models. More effective than 20 insulin injections. High safety profile across all toxicology assessments.
Shahriar, S M Shatil; An, Jeong Man; Surwase, Sachin S; Lee, Dong Yun; Lee, Yong-Kyu · Animal Study
RPEP-09243 · 2024Cardiac natriuretic peptides (ANP, BNP) serve dual clinical roles: as diagnostic biomarkers for heart failure (BNP and NT-proBNP blood tests are standard of care) and as therapeutic targets (sacubitril/valsartan inhibits neprilysin to increase natriuretic peptide levels). The system encompasses peptide hormones, specific receptors (NPR-A, NPR-B, NPR-C), and processing enzymes.
Shalmi, Theodor W; Jensen, Anne Sophie B; Goetze, Jens P · Review
RPEP-09244 · 2024GLP-1RAs vs placebo: weight -4.21 kg (CI -7.08 to -1.35), BMI -2.11 kg/m² (CI -3.60 to -0.62). Network meta-analysis ranking: semaglutide > exenatide > liraglutide > lixisenatide for weight reduction. Longer therapy duration associated with greater reductions. Consistent effects in T2DM subgroup.
Shamim, Muhammad Aaqib; Patil, Amol N; Amin, Ulfat; Roy, Tuli; Tiwari, Krishna; Husain, Noor; Kumar, Jogender; Chenchula, Santenna; Rao, Priyanka; Ganesh, Venkata; Varthya, Shoban Babu; Singh, Surjit; Shukla, Ravindra; Rastogi, Ashu; Gandhi, Aravind P; Satapathy, Prakisini; Sah, Ranjit; Padhi, Bijaya Kumar; Dwivedi, Pradeep; Khunti, Kamlesh · Meta Analysis
RPEP-09245 · 2024Liraglutide added to metformin significantly improved SBP, DBP, BMI, waist-hip ratio, glycolipid metabolism indices, and microinflammatory markers compared to metformin alone over 12 weeks (P<0.05). High medication safety reported.
Shao, Wei; Wu, Jianli; Zhu, Meiqin; Wang, Yanqi; Ci, Haideng · RCT
RPEP-09246 · 2024Three novel SNAC phenolate salts were successfully synthesized and shown to maintain equivalent oral pharmacokinetic performance for semaglutide delivery in vivo.
Shapira-Furman, Tovi; Bar-Hai, Ayala; Hoffman, Amnon; Domb, Abraham J · In Vitro
RPEP-09247 · 2024NPY levels are reduced in cerebrospinal fluid and plasma of Alzheimer's patients, and NPY demonstrates neuroprotective properties in both in vitro and in vivo AD models.
Shapovalova, Ksenia; Zorkina, Yana; Abramova, Olga; Andryushchenko, Alisa; Chekhonin, Vladimir; Kostyuk, Georgy · Review
RPEP-09248 · 2024Novel tripeptides triggered pro-inflammatory IL-12 and IFN-γ secretion from CD4+CD44+ T-cells in response to Leishmania donovani, promoting a protective TH1 immune response.
Sharma, Swati; Anand, Anshul; Singh, Rajan; Singh, Rakesh K; Verma, Sandeep · In Vitro
RPEP-09249 · 2024N-terminal histidine of liraglutide reacts with formaldehyde impurities in excipients and PLGA degradation products, forming imidazopyrimidine, glycolyl, and lactolyl interaction products.
Sheikh, Azahar R; Vitore, Jyotsna G; Bhalekar, Vijay S; Jain, Sonali; Kukreja, Divya; Giri, Tushar; Sharma, Nitish; Benival, Derajram; Shah, Ravi P · In Vitro
RPEP-09250 · 2024Exendin-4 suppressed ferroptosis in diabetic kidney tubular cells by activating AMPK-fatty acid metabolism signaling, reducing iron overload and lipid peroxidation through macropinocytosis-dependent cellular uptake.
Shen, Rui; Qin, Songyan; Lv, Yunhui; Liu, Dandan; Ke, Qingqing; Shi, Caifeng; Jiang, Lei; Yang, Junwei; Zhou, Yang · In Vitro
RPEP-09251 · 2024Three cryo-EM structures of Gi2-coupled Y1R and Y2R with NPY revealed a conserved peptide-binding mode and an additional sub-pocket conferring ligand selectivity, with evidence of evolutionary adaptation in this selectivity region.
Shen, Siyuan; Deng, Yue; Shen, Chenglong; Chen, Haidi; Cheng, Lin; Wu, Chao; Zhao, Chang; Yang, Zhiqian; Hou, Hanlin; Wang, Kexin; Shao, Zhenhua; Deng, Cheng; Ye, Feng; Yan, Wei · In Vitro
RPEP-09252 · 2024Twelve weeks of liraglutide (1.8mg) in post-bariatric patients with persistent obesity produced 11.6% total weight loss versus 4.9% in controls, with an estimated treatment difference of 6.6% and improved metabolic outcomes.
Shen, Yuanyuan; Huang, Yuanhao; Ouyang, Yuqin; Xiang, Xinyue; Chu, Xuehui; Zhang, Bingqing; Han, Tao; Tang, Wenjuan; Feng, Wenhuan · Cohort
RPEP-09253 · 2024Non-alcoholic Wernicke encephalopathy occurred in a 37-year-old male patient in the setting of semaglutide use, presenting with dysphagia, slurred speech, word-finding difficulty, and restricted extraocular movements.
Sheth, Krishna; Garza, Elizabeth; Saju, Ajith; Nazir, Natasha; Agarwal, Aditya · Case Series
RPEP-09254 · 2024Liraglutide protected endothelial cells from high glucose-induced apoptosis, oxidative stress, inflammasome activation, and pyroptosis by regulating the TRIB3/NF-κB/IκB-α signaling pathway.
Shi, Lili; Xu, Yingying; Zhao, Chao; Qu, Guangjin; Hao, Ming · In Vitro
RPEP-09255 · 2024Dulaglutide caused significant elevation of serum CA19-9 and CA242 levels in an asymptomatic patient, which completely normalized within 6 weeks of drug discontinuation.
Shi, Xiaomin · Case Series
RPEP-09256 · 2024CGRP mAbs reduced monthly migraine days from 13.4 to 7.4 (p<0.0001) with a 50% response rate, and early response after 1-2 doses predicted sustained benefit at 3 doses (OR: 3.474, p=0.047).
Shibata, Mamoru; Fujita, Kazuki; Hoshino, Eri; Minami, Kazushi; Koizumi, Kenzo; Okada, Satoshi; Sakai, Fumihiko · Cohort
RPEP-09257 · 2024Galcanezumab completely prevented migraine aura without headache within one day of first administration in a patient with a 39-year history of the condition.
Shibata, Yasushi · Case Series
RPEP-09258 · 2024CPPs penetrate skin through molecular interactions with the lipid lamellar structure between corneocytes in the stratum corneum, enabling transdermal delivery of macromolecules for therapeutic and cosmetic applications.
Shin, Hee Je; Lee, Byung Kyu; Kang, Hyun Ah · Review
RPEP-09259 · 2024Lu-177 DOTATATE PRRT in Korean NET patients achieved median PFS of 21.7 months, 20% ORR, and 88% one-year OS, with significantly better outcomes in grade 1-2 versus grade 3 tumors (HR 3.15, p=0.006).
Shin, Yeokyeong; Moon, Bo Hyun; Ryoo, Baek-Yeol; Chang, Heung-Moon; Kim, Kyu-Pyo; Hong, Yong Sang; Kim, Tae Won; Ryu, Jin-Sook; Kim, Yong-Il; Yoo, Changhoon · Cohort
RPEP-09260 · 2024GLP-1 receptor agonists showed significant inverse associations with MS: semaglutide ROR 0.238, dulaglutide ROR 0.165, liraglutide ROR 0.161 (all p<0.05), while non-GLP-1 weight-loss drugs showed no inverse association.
Shirani, Afsaneh; Cross, Anne H; Stuve, Olaf · Cohort
RPEP-09261 · 2024Three novel RuBisCO-derived peptides showed ACE-inhibitory activity: TTVW (IC50: 12.89 μM), TMW (IC50: 23.97 μM) as noncompetitive inhibitors, and VPCL (IC50: 339.12 μM) as a competitive inhibitor.
Shu, Haoyue; Zhao, Qingcui; Huang, Yu; Shi, Qiong; Yang, Jian · In Vitro
RPEP-09262 · 2024The 2023 VA/DoD guideline incorporates CGRP inhibitors (gepants for acute treatment, CGRP monoclonal antibodies and atogepant for prevention) as recommended options for migraine management alongside traditional treatments.
Sico, Jason J; Antonovich, Natasha M; Ballard-Hernandez, Jennifer; Buelt, Andrew C; Grinberg, Amy S; Macedo, Franz J; Pace, Ian W; Reston, James; Sall, James; Sandbrink, Friedhelm; Skop, Karen M; Stark, Thomas R; Vogsland, Rebecca; Wayman, Lisa; Ford, Aven W · Review
RPEP-09263 · 2024GLP-1RAs reduced risk of Alzheimer's (RR=0.627), Lewy body dementia (RR=0.590), and vascular dementia (RR=0.438). Semaglutide specifically reduced Parkinson's risk (RR=0.574) and showed the most pronounced protective effects across all disorders.
Siddeeque, Nabeela; Hussein, Mohammad H; Abdelmaksoud, Ahmed; Bishop, Julia; Attia, Abdallah S; Elshazli, Rami M; Fawzy, Manal S; Toraih, Eman A · Cohort
RPEP-09264 · 2024Combination therapies targeting energy metabolism pathways — including GLP-1 receptor agonists, PGK-1 enhancers, and A2A receptor modulators — may offer synergistic neuroprotection for Parkinson's disease.
Siddique, A H H; Kale, P P · Review
RPEP-09265 · 2024The evolution from single-target GLP-1 drugs to dual and triple receptor agonists is producing dramatically greater weight loss: tirzepatide (GIP/GLP-1) achieves 17.8% and retatrutide (GLP-1/GCG/GIP tri-agonist) achieves 22.1% placebo-subtracted weight reduction.
Sidrak, Wael R; Kalra, Sanjay; Kalhan, Atul · Review
RPEP-09266 · 2024Tumor uptake of Lu-177 DOTATATE decreased progressively: 86.9% (cycle 2), 79.7% (cycle 3), and 77.6% (cycle 4) of first-cycle levels. The plateau pattern suggests receptor downregulation is likely not the primary cause.
Siebinga, H; Hendrikx, J J M A; de Vries-Huizing, D M V; Huitema, A D R; de Wit-van der Veen, B J · Cohort
RPEP-09267 · 2024Anoplin conjugated to PNA via a non-cleavable ethylene glycol linker demonstrated antibacterial activity against E. coli and S. Typhimurium at 2-4 μM, establishing it as an effective new PNA carrier peptide.
Siekierska, Izabela; Burmistrz, Michał; Trylska, Joanna · In Vitro
RPEP-09268 · 2024BPC 157 counteracts advanced vascular occlusion syndromes by activating collateral rescuing pathways including azygos vein direct blood flow delivery, protecting multiple organs from ischemic damage across diverse experimental models.
Sikiric, Predrag; Sever, Marko; Krezic, Ivan; Vranes, Hrvoje; Kalogjera, Luka; Smoday, Ivan Maria; Vukovic, Vlasta; Oroz, Katarina; Coric, Luka; Skoro, Marija; Kavelj, Ivana; Zubcic, Slavica; Sikiric, Suncana; Beketic Oreskovic, Lidija; Oreskovic, Ivana; Blagaic, Vladimir; Brcic, Klara; Strbe, Sanja; Staresinic, Mario; Boban Blagaic, Alenka; Skrtic, Anita; Seiwerth, Sven · Review
RPEP-09269 · 2024Codfish skin collagen hydrolysates achieved 961 µmol TE antioxidant activity and 39.3% ACE inhibition. Chitosan-TPP encapsulation enabled 58% intestinal release in a simulated GI tract model.
Silva, Isa; Vaz, Bárbara M C; Sousa, Sérgio; Pintado, Maria Manuela; Coscueta, Ezequiel R; Ventura, Sónia P M · In Vitro
RPEP-09270 · 2024Lineage-tracing revealed a larger population of NPY neurons in the inferior colliculus than expression-tracking alone, and optogenetic experiments confirmed these neurons form local inhibitory synaptic circuits.
Silveira, Marina A; Herrera, Yoani N; Beebe, Nichole L; Schofield, Brett R; Roberts, Michael T · Animal Study
RPEP-09271 · 2024Across 64 randomized controlled trials, GLP-1 receptor agonist treatment was associated with a statistically significant increase in overall thyroid cancer risk, with a Mantel-Haenszel odds ratio of 1.52 (95% CI: 1.01–2.29, p=0.04). There was no significant heterogeneity between studies (I²=0%).
The fragility index was just 1, meaning a single event change would eliminate statistical significance. The 5-year number needed to harm was 1,349 — meaning approximately 1 extra thyroid cancer case per 1,349 patients treated for 5 years.
When restricted to trials lasting at least 104 weeks, the association strengthened slightly (OR 1.76, 95% CI: 1.00–3.12). However, neither papillary thyroid cancer (OR 1.54, p=0.22) nor medullary thyroid cancer (OR 1.44, p=0.55) reached significance individually.
Silverii, Giovanni Antonio; Monami, Matteo; Gallo, Marco; Ragni, Alberto; Prattichizzo, Francesco; Renzelli, Valerio; Ceriello, Antonio; Mannucci, Edoardo ·
RPEP-09272 · 2024Liraglutide achieved the smallest brain infarcts (2.9% vs 6.2% canagliflozin, vs 17.5% untreated DM). Both GLP-1RAs reduced hippocampal microglial activation while canagliflozin did not, indicating a unique anti-neuroinflammatory mechanism for GLP-1 drugs.
Simanenkova, Anna; Fuks, Oksana; Timkina, Natalya; Islamova, Alina; Sufieva, Dina; Kirik, Оlga; Korzhevskii, Dmitrii; Vlasov, Timur; Karonova, Tatiana · Animal Study
RPEP-09273 · 2024GLP-1 receptor agonists reduced the risk of late-onset seizures and epilepsy by 24% (RR: 0.76, 95% CI: 0.62-0.95) in a meta-analysis of 27 RCTs with ~200,000 patients. The benefit was specific to GLP-1 RAs, not DPP-4i or SGLT2i.
Sindhu, Udeept; Sharma, Akshay; Zawar, Ifrah; Punia, Vineet · Meta Analysis
RPEP-09274 · 2024Contemporary GLP-1-based medications and bariatric surgery are both effective for obesity management, with multiple FDA-approved GLP-1RAs and one GLP-1/GIP dual agonist now available alongside refined surgical techniques.
Singh, Abhayjit; Nissen, Steven E · Review
RPEP-09275 · 2024Dual receptor agonists tirzepatide (GIP/GLP-1) and survodutide (GCG/GLP-1) demonstrate higher rates of MASH resolution and fibrosis improvement compared to single GLP-1 agonists alone.
Singh, Anmol; Sohal, Aalam; Batta, Akash · Review
RPEP-09276 · 2024GLP-1 agonists promote beneficial gut bacteria, enhance gut barrier integrity, reduce systemic inflammation, and increase short-chain fatty acid production, collectively disrupting the obesity-dysbiosis-inflammation cycle.
Singh, Kanwarmandeep; Aulakh, Smriti K; Nijjar, Gurkamal Singh; Singh, Sumerjit; Sandhu, Ajay Pal Singh; Luthra, Shivansh; Tanvir, Fnu; Kaur, Yasmeen; Singla, Abhinandan; Kaur, Meet Sirjana · Review
RPEP-09277 · 2024CART neuropeptide was characterized for the first time in a reptilian brain (gecko), showing >93% similarity to mammalian CART peptides and regulation by NPY via Y1 receptors in the hypothalamic arcuate nucleus.
Singh, Omprakash; Basu, Sumela; Srivastava, Abhinav; Pradhan, Dipti R; Dandapat, Pallabi; Bathrachalam, Chandramohan; Singru, Praful S · Animal Study
RPEP-09278 · 2024A single-application microneedle patch with 4 programmable core-shell pixels achieves sequential weekly semaglutide release over one month, simulating 4 separate bolus injections from one painless skin application.
Singh, Parbeen; Vinikoor, Tra; Sharma, Nidhi; Nelson, Nicole; Prasadh, Somasundaram; Oiknine, Ralph; Nguyen, Thanh Duc · In Vitro
RPEP-09279 · 2024Raynaud's phenomenon was identified as a novel safety signal for all CGRP antagonists using FAERS data mining (PRR ≥2, chi-square ≥4, ROR lower 95% CI >2), with IGF1R pathway involvement suggested by network pharmacology.
Singh, Rima; Kumar, Anoop; Lather, Viney; Sharma, Ruchika; Pandita, Deepti · Cohort
RPEP-09280 · 2024Prolactin produces female-selective sensory neuron sensitization and enhanced CGRP release across species (mice, primates, humans), and clinical data indicate CGRP-receptor antagonists may be preferentially effective in women for acute migraine.
Singh, Shagun; Kopruszinski, Caroline M; Watanabe, Moe; Dodick, David W; Navratilova, Edita; Porreca, Frank · Review